Duo Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Duo Wang has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Guanhua Qiu
7 shared publicationsQin Wang
7 shared publicationsXiaoqi Zhu
6 shared publicationsJunjie Liu
Department of Medical Ultrasound, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Guangxi Medical University. Nanning 530021, China
5 shared publicationsJuan Qin
Southeast University
4 shared publicationsShanshan Ma
4 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Advanced Science
Glutaminolysis Blockade‐Empowered Bimodal Nanodepot for Spatially Complementary Sono‐Thermal Ablation via PANoptosis and STING Activation Against Large Tumors
Microwave ablation (MWA) for large hepatocellular carcinoma (HCC) is frequently compromised by non‐uniform thermal distribution and immunosuppressive niche formation. To address these challenges, we engineered an injectable bimodal nanodepot (TCPD) via catalytic crosslinking of dopamine‐modified hyaluronic acid by microwave thermal converter cesium‐doped Prussian blue, enabling co‐delivery of glutaminase 1 inhibitor Telaglenastat and sonosensitizer Chlorin e6. Under combined MWA and ultrasound irradiation, TCPD nanodepot disrupts cellular antioxidant defenses and bioenergetic pathways through glutaminolysis‐TCA cycle blockade, metabolically sensitizing large tumors to spatially complementary sono‐thermal ablation and enabling complete treatment coverage. This multimodal intervention induces multiple subcellular stresses, including mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD + depletion, which converge to facilitate PANoptosome assembly and immunogenic PANoptosis while activating the cGAS‐STING pathway. Subsequent release of damage‐associated molecular patterns and immunoregulatory cytokines promotes dendritic cell maturation, M1 macrophage polarization, and T lymphocyte infiltration, ultimately reprogramming the immunosuppressive microenvironment toward an immune‑activated niche. Integration with anti‐PD‐1 therapy further reinvigorates cytotoxic T lymphocytes and establishes antitumor immune memory to suppress tumor progression and metastasis, offering a multimodal therapeutic strategy for large HCC.
- 27 September 2026
- Published by Wiley in Advanced Science
Open AccessGlutaminolysis Blockade‐Empowered Bimodal Nanodepot for Spatially Complementary Sono‐Thermal Ablation via PANoptosis and STING Activation Against Large Tumors
Microwave ablation (MWA) for large hepatocellular carcinoma (HCC) is frequently compromised by non‐uniform thermal distribution and immunosuppressive niche formation. To address these challenges, we engineered an injectable bimodal nanodepot (TCPD) via catalytic crosslinking of dopamine‐modified hyaluronic acid by microwave thermal converter cesium‐doped Prussian blue, enabling co‐delivery of glutaminase 1 inhibitor Telaglenastat and sonosensitizer Chlorin e6. Under combined MWA and ultrasound irradiation, TCPD nanodepot disrupts cellular antioxidant defenses and bioenergetic pathways through glutaminolysis‐TCA cycle blockade, metabolically sensitizing large tumors to spatially complementary sono‐thermal ablation and enabling complete treatment coverage. This multimodal intervention induces multiple subcellular stresses, including mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD + depletion, which converge to facilitate PANoptosome assembly and immunogenic PANoptosis while activating the cGAS‐STING pathway. Subsequent release of damage‐associated molecular patterns and immunoregulatory cytokines promotes dendritic cell maturation, M1 macrophage polarization, and T lymphocyte infiltration, ultimately reprogramming the immunosuppressive microenvironment toward an immune‑activated niche. Integration with anti‐PD‐1 therapy further reinvigorates cytotoxic T lymphocytes and establishes antitumor immune memory to suppress tumor progression and metastasis, offering a multimodal therapeutic strategy for large HCC.
- 21 September 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (39) , 26698-26714
Dual-Stimuli-Driven Calcium Nanomachines for NO-Induced Immunogenic Cell Death
Tumor blood vascular endothelial cells targeting has emerged as a powerful strategy to enhance the accumulation and penetration of nanomedicines. However, the complex tumor microenvironment, especially the newly discovered breast cancer blood vascular basement membrane, can severely trap accumulated nanomedicines and compromise therapeutic efficacy. In this study, a γ-glutamyl transpeptidase (GGT)-targeting calcium nanomachine is designed and fabricated through decoration of GGT-targeting polysarcosine and encapsulation of nitric oxide (NO) precursors. Upon NIR laser irradiation, these calcium nanomachines can efficiently release NO on demand. By integration of the GGT-targeting and NIR-triggered NO release, these nanomachines can actively target the 4T1 tumor, deeply penetrate into tumor region, and are efficiently internalized by 4T1 cells. Robust tumor cell apoptosis and immunogenic cell death (ICD) can be achieved as well as efficient immune activation. Meanwhile, these calcium nanomachines can also greatly inhibit 4T1 lung metastasis and demonstrate significant efficacy against large tumors. This work offers a great opportunity for the facile design and construction of precision nanomedicines.
- 21 September 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (39) , 26698-26714
Dual-Stimuli-Driven Calcium Nanomachines for NO-Induced Immunogenic Cell Death
Tumor blood vascular endothelial cells targeting has emerged as a powerful strategy to enhance the accumulation and penetration of nanomedicines. However, the complex tumor microenvironment, especially the newly discovered breast cancer blood vascular basement membrane, can severely trap accumulated nanomedicines and compromise therapeutic efficacy. In this study, a γ-glutamyl transpeptidase (GGT)-targeting calcium nanomachine is designed and fabricated through decoration of GGT-targeting polysarcosine and encapsulation of nitric oxide (NO) precursors. Upon NIR laser irradiation, these calcium nanomachines can efficiently release NO on demand. By integration of the GGT-targeting and NIR-triggered NO release, these nanomachines can actively target the 4T1 tumor, deeply penetrate into tumor region, and are efficiently internalized by 4T1 cells. Robust tumor cell apoptosis and immunogenic cell death (ICD) can be achieved as well as efficient immune activation. Meanwhile, these calcium nanomachines can also greatly inhibit 4T1 lung metastasis and demonstrate significant efficacy against large tumors. This work offers a great opportunity for the facile design and construction of precision nanomedicines.
- 6 September 2026
- Published by Elsevier in Chemical Engineering Journal
- Vol. 548
Interference with ammonia metabolism by nano-immunomodulator to impede T cell exhaustion after incomplete radiofrequency ablation
- 6 September 2026
- Published by Elsevier in Chemical Engineering Journal
- Vol. 548
Interference with ammonia metabolism by nano-immunomodulator to impede T cell exhaustion after incomplete radiofrequency ablation
- Open Access
- 6 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9474
PPARα activation overcomes fibroinflammatory liver microenvironment-associated anti-PD-1 resistance in hepatocellular carcinoma by mediating GSDME-dependent pyroptosis
The fibroinflammatory liver microenvironment (FILM), characterized by collagen-rich stroma and immunosuppressive inflammation, is prevalent in hepatocellular carcinoma (HCC) and correlates with poor response to programmed cell death protein 1 (PD-1) blockade. Here, we show that FILM suppresses gasdermin E (GSDME)-dependent pyroptosis and promotes immune suppression and anti-PD-1 resistance. Mechanistically, FILM-associated cancer-associated fibroblasts recruit and polarize macrophages toward a nitric oxide synthase 2 (NOS2)⁺ inflammatory phenotype. NOS2+ macrophage-derived nitric oxide induces SP1 S-nitrosylation, impairs SP1 binding to the peroxisome proliferator-activated receptor alpha (PPARA) promoter and transcriptionally represses PPARA in HCC cells. PPARα downregulation reduces pyruvate dehydrogenase kinase 4 (PDK4) expression, mitochondrial reactive oxygen species production, caspase-3 activation and GSDME cleavage. Conversely, ligand activation of tumor intrinsic PPARα restores the PDK4–ROS–caspase-3–GSDME axis, enhances dendritic cell and CD8⁺ T cell activation, and sensitizes HCC to anti–PD-1 therapy. The clinically approved PPARα agonist fenofibrate enhances anti-PD-1 efficacy in HCC models in male mice and is associated with improved clinical benefit in a retrospective cohort of patients with HCC. We propose a FILM–NOS2–SP1–PPARα–PDK4 axis that controls pyroptotic immunogenicity and immunotherapy response, supporting PPARα activation as a strategy to overcome FILM-associated immune resistance in HCC.
- 6 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9474
Open AccessPPARα activation overcomes fibroinflammatory liver microenvironment-associated anti-PD-1 resistance in hepatocellular carcinoma by mediating GSDME-dependent pyroptosis
The fibroinflammatory liver microenvironment (FILM), characterized by collagen-rich stroma and immunosuppressive inflammation, is prevalent in hepatocellular carcinoma (HCC) and correlates with poor response to programmed cell death protein 1 (PD-1) blockade. Here, we show that FILM suppresses gasdermin E (GSDME)-dependent pyroptosis and promotes immune suppression and anti-PD-1 resistance. Mechanistically, FILM-associated cancer-associated fibroblasts recruit and polarize macrophages toward a nitric oxide synthase 2 (NOS2)⁺ inflammatory phenotype. NOS2+ macrophage-derived nitric oxide induces SP1 S-nitrosylation, impairs SP1 binding to the peroxisome proliferator-activated receptor alpha (PPARA) promoter and transcriptionally represses PPARA in HCC cells. PPARα downregulation reduces pyruvate dehydrogenase kinase 4 (PDK4) expression, mitochondrial reactive oxygen species production, caspase-3 activation and GSDME cleavage. Conversely, ligand activation of tumor intrinsic PPARα restores the PDK4–ROS–caspase-3–GSDME axis, enhances dendritic cell and CD8⁺ T cell activation, and sensitizes HCC to anti–PD-1 therapy. The clinically approved PPARα agonist fenofibrate enhances anti-PD-1 efficacy in HCC models in male mice and is associated with improved clinical benefit in a retrospective cohort of patients with HCC. We propose a FILM–NOS2–SP1–PPARα–PDK4 axis that controls pyroptotic immunogenicity and immunotherapy response, supporting PPARα activation as a strategy to overcome FILM-associated immune resistance in HCC.
- Open Access
- 18 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (21) , 15384-15409
Injectable Binary-Amplified Cascade Hydrogels Suppress Post-Incomplete Microwave Ablation Relapse via Integrated Metallo-Metabolic-Immunomodulation
Hepatocellular carcinoma (HCC) relapse following incomplete microwave ablation (iMWA) represents a formidable clinical challenge. This progression is fueled by residual tumor cells that exhibit cell death resistance and dysregulated fatty acid metabolism, while exploiting a myeloid-derived immunosuppressive microenvironment. To address this limitation, we developed an injectable binary-amplified cascade hydrogel (S/CuCo@HD) that co-delivers CD36 inhibitor sulfosuccinimidyl oleate (SSO) and a copper-cobalt bimetal-organic framework (Cu-Co BMF). Locally administered S/CuCo@HD serves as a reservoir for sustained-release SSO and Cu-Co BMF within tumor cavities post-iMWA, provoking self-reinforced lipid oxygen radical storm by collaborative SSO-mediated fatty acid composition rewiring and peroxidase-mimetic Cu-Co BMF catalysis. The binary amplified radical reaction together with Cu2+-triggered cuproptosis culminates in a binary-amplified mitochondria crisis and subsequent the cytosolic release of damaged DNA fragments. Critically, these danger signals function as a pivotal immunological switch, sequentially initiating binary-amplified STING activation with Co2+ potentiation while simultaneously inducing robust ICD. The consequent release of damage-associated molecular patterns and interferon-β promotes dendritic cell maturation, polarizes macrophages toward an M1 phenotype, and facilitates T-cell infiltration, ultimately reprogramming the immunosuppressive microenvironment into an immune-activated niche. Crucially, S/CuCo@HD synergizes with anti-PD-1 therapy to reinvigorate cytotoxic T lymphocytes and establish durable immune memory, effectively suppressing tumor relapse and metastasis post-iMWA, offering an integrated metallo-metabolic-immunomodulation strategy with promising translational potential for comprehensive HCC management.
- 18 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (21) , 15384-15409
Open AccessInjectable Binary-Amplified Cascade Hydrogels Suppress Post-Incomplete Microwave Ablation Relapse via Integrated Metallo-Metabolic-Immunomodulation
Hepatocellular carcinoma (HCC) relapse following incomplete microwave ablation (iMWA) represents a formidable clinical challenge. This progression is fueled by residual tumor cells that exhibit cell death resistance and dysregulated fatty acid metabolism, while exploiting a myeloid-derived immunosuppressive microenvironment. To address this limitation, we developed an injectable binary-amplified cascade hydrogel (S/CuCo@HD) that co-delivers CD36 inhibitor sulfosuccinimidyl oleate (SSO) and a copper-cobalt bimetal-organic framework (Cu-Co BMF). Locally administered S/CuCo@HD serves as a reservoir for sustained-release SSO and Cu-Co BMF within tumor cavities post-iMWA, provoking self-reinforced lipid oxygen radical storm by collaborative SSO-mediated fatty acid composition rewiring and peroxidase-mimetic Cu-Co BMF catalysis. The binary amplified radical reaction together with Cu2+-triggered cuproptosis culminates in a binary-amplified mitochondria crisis and subsequent the cytosolic release of damaged DNA fragments. Critically, these danger signals function as a pivotal immunological switch, sequentially initiating binary-amplified STING activation with Co2+ potentiation while simultaneously inducing robust ICD. The consequent release of damage-associated molecular patterns and interferon-β promotes dendritic cell maturation, polarizes macrophages toward an M1 phenotype, and facilitates T-cell infiltration, ultimately reprogramming the immunosuppressive microenvironment into an immune-activated niche. Crucially, S/CuCo@HD synergizes with anti-PD-1 therapy to reinvigorate cytotoxic T lymphocytes and establish durable immune memory, effectively suppressing tumor relapse and metastasis post-iMWA, offering an integrated metallo-metabolic-immunomodulation strategy with promising translational potential for comprehensive HCC management.
- 3 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114900
Targeted microwave sensitizers reprogram cancer-associated fibroblasts via nitric oxide delivery to potentiate hepatocellular carcinoma therapy
- 3 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114900
Targeted microwave sensitizers reprogram cancer-associated fibroblasts via nitric oxide delivery to potentiate hepatocellular carcinoma therapy
- Open Access
- 3 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102892
A biomimetic magnetic MOF-based nanoplatform for H2S-mediated thermal re-sensitization and immune reprogramming in multimodal hyperthermia therapy
- 3 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102892
Open AccessA biomimetic magnetic MOF-based nanoplatform for H2S-mediated thermal re-sensitization and immune reprogramming in multimodal hyperthermia therapy
- Open Access
- 19 January 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1) , 42
Correction: Mesoporous multimetallic PdPtBi nanozymes target redox imbalance and glutamine deprivation for immuno-chemodynamic therapy
- 19 January 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1) , 42
Open AccessCorrection: Mesoporous multimetallic PdPtBi nanozymes target redox imbalance and glutamine deprivation for immuno-chemodynamic therapy
- Open Access
- 24 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Mesoporous multimetallic PdPtBi nanozymes target redox imbalance and glutamine deprivation for immuno-chemodynamic therapy
Therapeutic resistance remains a formidable challenge in oncology, mainly due to the chaotic tumor microenvironment (TME), which drive tumor progression and adaptive resistance via a self-sustaining metabolic–oxidative feedback loop. Herein, a multifunctional nanotherapeutic platform based on PdPtBi multimetallic nanozymes (PPB MMNs) is rationally engineered to address these challenges by simultaneously targeting reactive oxygen species (ROS) modulation and glutamine (Gln) metabolic disruption. Specifically, the PPB MMNs display cascade enzyme-mimicking activities resembling peroxidase (POD), catalase (CAT), and glutathione oxidase (GOD-SH). These activities effectively promote the generation of reactive oxygen species (ROS) and facilitate the decomposition of endogenous H₂O₂ into O₂, thereby alleviating hypoxia and inducing oxidative stress. Upon ultrasound (US) activation, their catalytic performance is further amplified, enabling deep-tissue therapeutic efficacy. Concurrently, PPB MMNs impair Gln metabolism, aggravating redox dyshomeostasis and undermining tumor metabolic flexibility. Both in vitro and in vivo studies validate the superior antitumor activity of PPB MMNs in suppressing primary and metastatic tumor growth by disrupting the redox-metabolic axis. Collectively, our study offers a robust framework for designing multimodal nanomedicines that reprogram the TME and overcome resistance, opening new avenues for precise, synergistic cancer therapy based on redox and metabolic vulnerabilities.
- 24 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Open AccessMesoporous multimetallic PdPtBi nanozymes target redox imbalance and glutamine deprivation for immuno-chemodynamic therapy
Therapeutic resistance remains a formidable challenge in oncology, mainly due to the chaotic tumor microenvironment (TME), which drive tumor progression and adaptive resistance via a self-sustaining metabolic–oxidative feedback loop. Herein, a multifunctional nanotherapeutic platform based on PdPtBi multimetallic nanozymes (PPB MMNs) is rationally engineered to address these challenges by simultaneously targeting reactive oxygen species (ROS) modulation and glutamine (Gln) metabolic disruption. Specifically, the PPB MMNs display cascade enzyme-mimicking activities resembling peroxidase (POD), catalase (CAT), and glutathione oxidase (GOD-SH). These activities effectively promote the generation of reactive oxygen species (ROS) and facilitate the decomposition of endogenous H₂O₂ into O₂, thereby alleviating hypoxia and inducing oxidative stress. Upon ultrasound (US) activation, their catalytic performance is further amplified, enabling deep-tissue therapeutic efficacy. Concurrently, PPB MMNs impair Gln metabolism, aggravating redox dyshomeostasis and undermining tumor metabolic flexibility. Both in vitro and in vivo studies validate the superior antitumor activity of PPB MMNs in suppressing primary and metastatic tumor growth by disrupting the redox-metabolic axis. Collectively, our study offers a robust framework for designing multimodal nanomedicines that reprogram the TME and overcome resistance, opening new avenues for precise, synergistic cancer therapy based on redox and metabolic vulnerabilities.
- Open Access
- 14 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (1) , 522-538
Engineered bacterial extracellular vesicles mediate pyroptosis to counteract m6A methylation-based immunosuppression after insufficient radiofrequency ablation of hepatocellular carcinoma
- 14 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (1) , 522-538
Open AccessEngineered bacterial extracellular vesicles mediate pyroptosis to counteract m6A methylation-based immunosuppression after insufficient radiofrequency ablation of hepatocellular carcinoma